Cabaletta Bio(CABA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 abaletta Bio Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update – Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data from the RESET-Myositis™ and RESET-SLE™ trials as well as initial clinical data from the RESET-SSc™ and RESET-MG™ trials anticipated in 2H24 – – Initial clinical and translational data from each o ...